Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Autologous stem cell transplantation (ASCT) is a standard of care treatment for patients with multiple myeloma (MM). However, only 20% to 30% of patients with MM for whom the procedure is indicated undergo ASCT. Barriers to ASCT may be informational, financial, logistic, or cultural and may affect patients and treating oncologists. Available and accessible accurate ASCT-related information is essential to overcome these barriers. Such resources can be created by blood and marrow transplantation societies and patient advocacy groups, ideally in collaboration with MM specialists at transplant centers. An umbrella office at the society level is also recommended to connect oncologists, advocacy groups, and transplantation specialists; provide informational resources to patients; and conduct research into region- and population-specific barriers to ASCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtct.2023.08.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generation of humanized bone for disease modeling using porcine adipose tissue-derived extracellular matrix scaffolds and human dental pulp stem cells.
Methods Cell Biol
September 2025
Department of Cell Biology and Histology, University of the Basque Country UPV/EHU, Leioa, Spain. Electronic address:
Human Dental Pulp Stem Cells (hDPSCs) represent a remarkable cell source for tissue engineering and regenerative medicine, offering significant potential for use in personalized medicine and autologous therapies. Decellularized extracellular matrix (ECM)-derived biological scaffolds show excellent properties for supporting cell delivery and growth in both in vitro and in vivo applications. These scaffolds provide essential biochemical cues that regulate cellular functions and offer a more accurate representation of the in vivo environment.
View Article and Find Full Text PDFComparison of autologous and allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia in Japan.
Transplant Cell Ther
September 2025
Division of Hematology and Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan. Electronic address:
Primary plasma cell leukemia (pPCL) is a rare and aggressive subtype of plasma cell malignancy. Although hematopoietic stem cell transplantation (HCT), including autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT), is widely used, an optimal treatment strategy is undetermined. We retrospectively analyzed patients with pPCL who underwent HCT between 2006 and 2022 in Japan using Japanese registry data.
View Article and Find Full Text PDFTrends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers.
Transfus Apher Sci
September 2025
Terumo Blood and Cell Technologies, Zaventem, Belgium. Electronic address:
Background: This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.
Methods: This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.
Vasculogenic potential of adipose tissue derived stem cells from patients with chronic spinal cord injury and pressure injuries.
Angiogenesis
September 2025
Pathophysiology and Regenerative Medicine Group, Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla la Mancha (SESCAM), 45071, Toledo, Spain.
Limited vascularization and ischemia are major contributors to the chronicity of wounds, such as ulcers and traumatic injuries, which impose significant medical, social, and economic burdens. These challenges are particularly pronounced in patients with spinal cord injury (SCI), a disabling condition associated with vascular dysfunction, infections, and impaired peripheral circulation, complicating the treatment of pressure injuries (PIs) and the success of reconstructive procedures like grafts and flaps. Regenerative medicine aims to address these issues by identifying effective cellular therapies to restore vascular beds.
View Article and Find Full Text PDF